No Data
LUYE PHARMA (02186.HK) has completed the issuance of 50 million US dollars in convertible Bonds maturing in 2025.
On December 13, Gelonghui reported that LUYE PHARMA (02186.HK) announced the issuance of $50 million convertible Bonds with a 5.85% interest rate maturing in 2025. All prerequisites for the issuance of Series B Bonds under the subscription agreement have been met, and the issuance of Series B Bonds has been successfully completed. The listing of Series B Bonds on the Singapore Exchange is expected to take effect on December 16, 2024.
LUYE PHARMA (02186) has completed the issuance of 50 million US dollars in convertible Bonds.
LUYE PHARMA (02186) announced the issuance of 50 million US dollars at an interest rate of 5.85%, maturing in 2025...
Luye Pharma Files for Singapore Listing of $50 Million of Bonds Due in 2025
Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
Hong Kong stock concept tracking | The biocontrol bill was not included in the latest version of NDAA. Institutions are bullish on the bottom opportunities in the CXO sector (with concept stocks attached).
On December 7, 2024, local time in the USA, the US Congressional Armed Services Committees in both the House and the Senate released the final agreement text of the 2025 National Defense Authorization Act (NDAA), which incorporates proposals from both chambers.
Honkong stock market movement | CRO concept stocks collectively opened higher as the bioprotective legislation was not included in the final version of the NDAA by the U.S. Senate and House of Representatives.
CRO concept stocks opened higher collectively. As of the time of writing, wuxi bio (02269) increased by 13.03%, trading at 19.6 Hong Kong dollars; wuxi apptec (02359) rose by 11.72%, trading at 61 Hong Kong dollars; pharmaron (03759) climbed by 9.14%, trading at 16 Hong Kong dollars.
